Anti-IL-20 [h15D2 (Fletikumab)]

Absolute Antibody

Anti-IL-20 [h15D2 (Fletikumab)]

9

This antibody can bind recombinant human IL-20 in an ELISA. This antibody was capable or neutralizing human IL20, cynomolgus IL20 and mouse IL20 induced proliferation of BaF-3(hIL20R) cells. This antibody can detect both native and denatured form of human IL-20 in a western blot. The original IgG4 version of this antibody, expressed in HEK293 cells, reacts with recombinant human IL-20 with a binding affinity of Kd= 32 pM (US8287861). It shows a very high potency in blocking IL-20 mediated activity on IL-20RA/IL-20RB and IL-22RA1/IL20R2 expressing cells with an IC50 value of 0.27 nM. It has a serum half-life of ~3 weeks in RA (Rheumatoid Arthritis) patients. Under the dose range from 0.05 to 3.0 mg/kg, Fletikumab was tolerable and non-toxic in patients with psoriasis. However, the clinical study was terminated because no apparent efficacy was observed. In the phase 2a trial, Fletikumab significantly reduced tender joint counts and swollen joint counts in seropositive RA patients (PMID: 30319661).

Western Blot, ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

h15D2 (Fletikumab)

IL20

interleukin 20

cytokine Zcyto10; four alpha helix cytokine; IL10D; IL-20; interleukin-20; ZCYTO10

Human

IgG1

Interleukin-20

-20°C,2°C to 8°C

12352203